DSpace@İnönü

Yazar "Paksoy, N" için Araştırma Çıktıları | Wos İndeksli Yayınlar Koleksiyonu listeleme

Yazar "Paksoy, N" için Araştırma Çıktıları | Wos İndeksli Yayınlar Koleksiyonu listeleme

Sırala: Sıra: Sonuçlar:

  • The real-life efficacy and safety of osimertinib in pretreated advanced 
    Hizal, M; Bilgin, B; Paksoy, N; Acikgoz, O; Sezer, A; Gurbuz, M; Ak, N; Yucel, S; Ayhan, M; Erol, C; Demirkiran, A; Mandel, NM; Shbair, A; Gokmen, I; Basoglu, T; Paydas, S; Demiray, AG; Iriagac, Y; Sakalar, T; Zeynelgil, E; Tatli, AM; Bahceci, A; Guven, DC; Caner, B; Can, A; Gulmez, A; Karakas, Y; Yalcin, B; Demirkazik, A; Bilici, A; Aydiner, A; Yumuk, PF; Sendur, MAN (2022)
    Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ...
  • Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment 
    Tasci, ES; Oyan, B; Sonmez, O; Mutlu, AU; Atci, MM; Oner, I; Cinkir, HY; Eryilmaz, MK; Balcik, OY; Paksoy, N; Salim, DK; Ozen, M; Ozcelik, M; Arican, A; Inal, A; Akagunduz, B; Aydin, D; Ozer, L; Turhal, NS; Gulmez, A (2022)
  • Real-world data on efficacy and safety of first-line alectinib treatment 
    Hizal, M; Bilgin, B; Paksoy, N; Kilickap, S; Atci, MM; Kahraman, S; Keskinkilic, M; Bilgetekin, I; Ayhan, M; Tural, D; Eren, O; Mustafayev, FNA; Yaman, S; Tatli, AM; Bayram, E; Kutlu, Y; Erturk, I; Ozcan, E; Gulmez, A; Korkmaz, M; Akagunduz, B; Erdem, D; Telli, TA; Aksoy, A; Uskent, N; Iriagac, Y; Baytemur, NK; Aydin, D; Sakalar, T; Arak, H; Selcukbiricik, F; Ergun, Y; Korkmaz, T; Ak, N; Unal, C; Akdeniz, N; Ozgun, MA; Oksuzoglu, B; Yalcin, B; Oztop, I; Algin, E; Sakin, A; Aydiner, A; Yumuk, PF; Sendur, MAN (2022)
    Plain language summary The advancements in cancer treatment, particularly in the last two decades, have been promising. Non-small-cell lung cancer (NSCLC) is one of the most important diseases experiencing these promising ...
  • Prognostic factors of perioperative FLOT regimen in operable gastric and 
    Erol, C; Sakin, A; Basoglu, T; Ozden, E; Cabuk, D; Dogan, M; Oksuzoglu, B; Yildirim, HC; Oner, I; Eryilmaz, MK; Dulgar, O; Aydin, D; Dogan, N; Ozen, M; Hacibekiroglu, I; Ozdemir, N; Gurler, F; Paksoy, N; Karabulut, S; Aksoy, A; Hizal, M; Kahraman, S; Sen, E; Paydas, S; Cilbir, E; Firat, F; Akdeniz, N; Ozcelik, M; Oyman, A; Baytemur, NK; Acar, R; Almuradova, E; Karabulut, B; Sakalar, T; Arak, H; Degerli, E; Turker, S; Alan, O; Er, O; Tasci, ES; Demir, N; Cavdar, E; Turhal, S; Dede, DS; Akinci, MB; Yalcin, B; Yumuk, F; Yalcin, S; Sendur, MAN (2022)
    Background/aim: Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in ...
  • The percentage of ALK-positive cells and the efficacy of first-line 
    Hizal, M; Bilgin, B; Paksoy, N; Atci, MM; Kahraman, S; Kilickap, S; Guven, DC; Keskinkilic, M; Ayhan, M; Eren, O; Mustafayev, FNA; Yaman, S; Bayram, E; Erturk, I; Ozcan, E; Korkmaz, M; Akagunduz, B; Erdem, D; Telli, TA; Aksoy, A; Uskent, N; Baytemur, NK; Gulmez, A; Aydin, D; Sakalar, T; Arak, H; Tatli, AM; Ergun, Y; Ak, N; Unal, C; Ozgun, MA; Yalcin, B; Oztop, I; Algin, E; Sakin, A; Aydiner, A; Yumuk, PF; Sendur, MAN
    Introduction Alectinib is an effective second-generation ALK tyrosine kinase inhibitor (TKI) used in the first-line treatment of patients with advanced ALK-positive NSCLC. Recent studies demonstrated that the percentage ...